Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 30, 2021 08:00 ET
|
Viridian Therapeutics, Inc.
WALTHAM, Mass., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biotechnology company advancing new treatments for patients suffering...
Viridian Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for VRDN-001, an IGF-1R Antibody for the Treatment of Thyroid Eye Disease (TED)
November 15, 2021 07:00 ET
|
Viridian Therapeutics, Inc.
Phase 1/2 proof of concept trial for VRDN-001 is expected to report top line clinical data in the second quarter of 2022 WALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics,...
Viridian Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
November 04, 2021 16:05 ET
|
Viridian Therapeutics, Inc.
Submitted an investigational new drug (IND) application to the FDA for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease (TED) and expect to report Phase 1/2 proof of concept...
Viridian Therapeutics to Present at Upcoming Investor Conferences
November 03, 2021 16:05 ET
|
Viridian Therapeutics, Inc.
WALTHAM, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases but...
Viridian Therapeutics Submits Investigational New Drug Application for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, to the U.S. Food and Drug Administration
October 14, 2021 08:00 ET
|
Viridian Therapeutics, Inc.
- VRDN-001 program remains on track for key proof of concept clinical data in Thyroid Eye Disease patients in the second quarter of 2022 - WALTHAM, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) --...
Viridian Therapeutics to Present Preclinical Data on VRDN-001 and VRDN-002 at the 90th Annual Meeting of the American Thyroid Association
September 30, 2021 08:06 ET
|
Viridian Therapeutics, Inc.
WALTHAM, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but...
Viridian Therapeutics Announces Closing of Public Offering of Shares of Common Stock and Preferred Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
September 23, 2021 16:01 ET
|
Viridian Therapeutics, Inc.
WALTHAM, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but...
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock and Preferred Stock
September 21, 2021 00:22 ET
|
Viridian Therapeutics, Inc.
WALTHAM, Mass., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but...
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
September 20, 2021 16:01 ET
|
Viridian Therapeutics, Inc.
WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but...
Viridian Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
August 11, 2021 07:00 ET
|
Viridian Therapeutics, Inc.
Completed a successful pre-IND meeting with the FDA for VRDN-001, a differentiated monoclonal antibody targeting IGF-1R for the treatment of Thyroid Eye Disease On track to submit an IND filing...